Patent cliffs arent just a legal eventtheyre a supply-chain event.
When a drugs exclusivity ends, the market doesnt simply open. It re-prices. It re-routes. It re-allocates capacity. And it tests whether procurement teams have the data and operating …

Generic drug margins are under siegeand the pressure isnt coming from one place. Its coming from eight directions at once.
If youve worked in (or around) generic pharma long enough, youve heard the familiar story: Competition will compress pricing, but…

Branded pharmas revenue model is under siegeand its not just one threat. Its a stack of brutal, compounding forces that are quietly turning steady growth into structural pressure.
If youve spent any time around drug pricing, payer negotiations, and pat…

Generic drug competition isnt just about filing an ANDAits about decoding the FDAs Orange Book.
Most people think the race to market is won in the lab or in the legal brief. In reality, the winners often start earlierby reading the FDA Orange Book li…

Biopharma hiring is broken in a very specific way: we keep treating IP as a legal function instead of an operating system.
Thats the agitation. Heres the problem underneath it: when companies build IP portfolios, they dont just file patentsthey encode …

The Generic Cliff Doesnt ArriveIts Engineered.
If youve ever wondered why some pharma companies seem to beat expiring patents while others get hit with a sudden revenue drop, the answer is rarely luck. Its strategyoften executed years before the cale…

Patent thickets are the quiet tax on innovationand the playbook is getting sharper.
If youve ever wondered why some blockbuster biologics seem to never really go generic, the answer is rarely one single patent. Its usually a strategy: build a dense t…

AI Prior Art Search: How to Invalidate Key Drug Patents Before You Pay
Most investors dont lose because they picked the wrong science. They lose because they paid for a patent landscape that looked clean on paperuntil it wasnt.
In pharma, that gap betw…

Drug formulation patents are where generic timing gets wonor lost.
Most teams obsess over active ingredient (API) patents: the big, obvious claims that show up in every diligence deck. But the real competitive edge often hides in the less glamorous d…

Russias VED and SSM lists arent just bureaucratic footnotestheyre a timing mechanism for market entry. And for anyone planning generic launches into Russia, the real question isnt whether a patent expires. Its when the regulatory clock lines up with th…